Abstract
In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Current Pharmaceutical Design
Title: Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Volume: 16 Issue: 35
Author(s): Carine Munaut, Alain C. Colige and Charles A. Lambert
Affiliation:
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Abstract: In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Export Options
About this article
Cite this article as:
Munaut Carine, C. Colige Alain and A. Lambert Charles, Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455012
DOI https://dx.doi.org/10.2174/138161210794455012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Synthesis and Applications of Hydrogels in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine Dietary Phytochemicals in Cancer Signalling Pathways: Role of miRNA Targeting
Current Medicinal Chemistry PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Dendritic Cells and the Promise of Therapeutic Vaccines for Human Immunodeficiency Virus (HIV)-1
Current HIV Research Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Controlled Releases of FGF-2 and Paclitaxel from Chitosan Hydrogels and their Subsequent Effects on Wound Repair, Angiogenesis, and Tumor Growth
Current Drug Delivery The Use of Nimesulide and Its Analogues in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Law-Medicine Interfacing: Patenting of Human Genes and Mutations
Recent Patents on DNA & Gene Sequences Haptotactic Gradients for Directed Cell Migration: Stimulation and Inhibition Using Soluble Factors
Combinatorial Chemistry & High Throughput Screening Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Current Radiopharmaceuticals Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies in Genitourinary Cancers)
Current Drug Targets